BAX: Baxter International Inc. - Summary | Jitta

Baxter International Inc.

NYSE:BAX

Price
$81.73
Loss Chance
45.5%
5.95JITTA SCORE
25.05%Above Jitta Line
Jitta Ranking
54 / 823
1,013 / 4,769
Grow your money with Jitta Ranking. See details.
HISTORICAL JITTA SCORE
Jitta Factors
Growth Opportunity (23)
Recent Business Performance (45)
Financial Strength (89)
Return to Shareholders (45)
Competitive Advantage (57)
Jitta Signs
Revenue and EarningConsistent
Recent Business PerformanceEarning Growth Last Year
Operating MarginConsistent
Debt LevelLow Long Term Debt
Share RepurchaseEvery Year
Key Stats
Jitta Score
Jitta Line
5.95
25.05%
2.22
0.67%
Healthcare Equipment
5.20
65.72%
8.10
31.47%
0.70
100.00%
COMPANY DESCRIPTION
Baxter International Inc., through its subsidiaries, develops and provides a portfolio of healthcare products. The company operates through North and South America; Europe, Middle East and Africa; and Asia-Pacific segments. The company offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; renal replacement therapies and other organ support therapies focused in the intensive care unit; sterile intravenous (IV) solutions, IV therapies, infusion pumps, administration sets, and drug reconstitution devices; and parenteral nutrition therapies. It also provides biological products and medical devices, and surgical hemostat and sealant products used in surgical procedures for hemostasis, tissue sealing, and adhesion prevention; premixed and oncology drug platforms, inhaled anesthesia and critical care products, and pharmacy compounding services; and generic injectable pharmaceuticals. Its products are used in hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors’ offices, and by patients at home under physician supervision. The company sells its products through direct sales force, as well as through independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers in approximately 100 countries. It has an agreement with Celerity Pharmaceutical, LLC to develop acute care generic injectable premix and oncolytic molecules. Baxter International Inc. was founded in 1931 and is headquartered in Deerfield, Illinois.